US EditionScientists Reveal Encouraging Findings in First-in-Human Clinical Trial Evaluating HIV Vaccine Approach
MULTIPLE LOCATIONS INCLUDING THE U.S., KIGALI (RWANDA), AND TEMBISA (SOUTH AFRICA), AUG 4 – The Phase 1 trial showed a favorable safety profile and induced targeted immune responses in 97% of vaccinated participants, advancing HIV vaccine development efforts.
8 Articles
8 Articles
Scientists reveal encouraging findings in first-in-human clinical trial evaluating HIV vaccine approach
While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy being pursued by a team of researchers. The teams work shows new promise, according to data from a first-in-human clinical trial.
The Lawton Constitution
Phase 1 Clinical Ttrial of HIV Vaccine Starts in Africa to Evaluate Immune Responses to Highly Networked HIV T-Cell Epitopes
Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given.
A breakthrough may be coming in the fight against HIV: a therapy that only needs to be administered once to infants who may catch the disease from their parents seems promising.
More than 40 years after the onset of HIV, the search for a vaccine remains one of the greatest medical challenges. A promising new path, based on messenger RNA, could finally change the situation.This week in Futura Santé, we will talk about the latest advances in relation to AIDS.[
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
